Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3909 in Advanced Malignant Tumors
NCT04975204Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3909 in non-Hodgkin lymphoma (NHL), plasmacytoma, acute myeloid leukemia (AML) and 1 more, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity up to 18 months and Recommended Phase II Dose up to 18 months. Status: unknown.
02
Drugs
TQB3909
03
Conditions
non-Hodgkin lymphoma (NHL)plasmacytomaacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04975204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975204.